Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

43.12USD
15 Oct 2018
Change (% chg)

$-0.66 (-1.51%)
Prev Close
$43.78
Open
$43.65
Day's High
$43.71
Day's Low
$42.98
Volume
22,773,043
Avg. Vol
20,254,875
52-wk High
$45.81
52-wk Low
$33.20

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences Collaborates With Pfizer To Evaluate Cancer Drugs
Friday, 5 Oct 2018 07:00am EDT 

Oct 5 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES ANNOUNCES CLINICAL TRIAL COLLABORATION TO EVALUATE IBRANCE® (PALBOCICLIB) AND TALAZOPARIB IN COMBINATION WITH CB-839.CALITHERA BIOSCIENCES-TRIAL COLLABORATIONS TO EVALUATE PFIZER'S PALBOCICLIB & TALAZOPARIB, EACH IN COMBINATION WITH CO'S GLUTAMINASE INHIBITOR CB-839.CALITHERA BIOSCIENCES - AS PART OF COLLABORATION, PFIZER WILL PROVIDE PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL SUPPORT.CALITHERA BIOSCIENCES - TO INITIATE PHASE 1/2 CLINICAL TRIAL OF COMBINATION OF CB-839 PLUS TALAZOPARIB IN PATIENTS WITH RCC, AND TNBC IN Q1 OF 2019.  Full Article

Pfizer Announces CEO Succession
Monday, 1 Oct 2018 07:18am EDT 

Oct 1 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES CEO SUCCESSION.IAN READ TO SERVE AS EXECUTIVE CHAIRMAN OF BOARD OF DIRECTORS.ALBERT BOURLA TO BECOME CHIEF EXECUTIVE OFFICER (CEO).IAN READ TO SERVE AS EXECUTIVE CHAIRMAN OF BOARD OF DIRECTORS.IAN READ WILL TRANSITION FROM HIS CURRENT ROLE AS CHAIRMAN AND CEO TO EXECUTIVE CHAIRMAN OF PFIZER'S BOARD OF DIRECTORS..EFFECTIVE JANUARY 1, 2019, ALBERT BOURLA TO BECOME CHIEF EXECUTIVE OFFICER.  Full Article

Pfizer CEO Read to Step Aside at Year's End - WSJ
Monday, 1 Oct 2018 06:35am EDT 

Oct 1 (Reuters) - :PFIZER COO ALBERT BOURLA TO BECOME CEO; IAN READ TO SHIFT TO EXECUTIVE CHAIRMAN - WSJ, CITING SOURCES.  Full Article

U.S. FDA Approves Vizimpro For The First-Line Treatment Of Patients
Thursday, 27 Sep 2018 05:41pm EDT 

Sept 27 (Reuters) - Pfizer Inc ::U.S. FDA APPROVES VIZIMPRO® (DACOMITINIB) FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH EGFR-MUTATED METASTATIC NON-SMALL CELL LUNG CANCER.PFIZER INC - APPROVAL SUPPORTED BY DATA FROM PHASE 3 HEAD-TO-HEAD STUDY VERSUS. GEFITINIB.  Full Article

Pfizer Sets Quarterly Dividend Of $0.34 Per Share
Thursday, 27 Sep 2018 01:09pm EDT 

Sept 27 (Reuters) - Pfizer Inc ::PFIZER DECLARES 34-CENT FOURTH-QUARTER 2018 DIVIDEND.  Full Article

Sandoz Wins U.S. FDA's Approval For Busulfan - FDA Wesbite
Friday, 21 Sep 2018 02:35pm EDT 

Sept 21 (Reuters) - FDA ::SANDOZ INC WINS U.S. FDA'S APPROVAL FOR BUSULFAN - FDA WESBITE.  Full Article

Allogene Therapeutics Files For IPO Of Up To $100 Million
Friday, 14 Sep 2018 07:58am EDT 

Sept 14 (Reuters) - Allogene Therapeutics::ALLOGENE THERAPEUTICS INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING.SAYS IT INTENDS TO APPLY TO HAVE ITS COMMON STOCK LISTED ON NASDAQ GLOBAL SELECT MARKET UNDER THE SYMBOL "ALLO".SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, COWEN ARE AMONG UNDERWRITERS TO IPO.SAYS JEFFERIES IS AMONG UNDERWRITERS TO IPO.PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.SAYS PFIZER INC HAS 24.6 PERCENT HOLDING IN CO BEFORE THE IPO - SEC FILING.SAYS GILEAD SCIENCES INC HAS 8.4 PERCENT HOLDING IN CO BEFORE IPO.  Full Article

Pfizer Terminates Domagrozumab Clinical Studies For The Treatment Of Duchenne Muscular Dystrophy
Thursday, 30 Aug 2018 08:00am EDT 

Aug 30 (Reuters) - Pfizer Inc ::PFIZER TERMINATES DOMAGROZUMAB (PF-06252616) CLINICAL STUDIES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.PFIZER INC - PHASE 2 STUDY (B5161002), DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT.PFIZER INC - STUDIES WERE NOT TERMINATED FOR SAFETY REASONS.PFIZER INC - EVALUATION OF TOTALITY OF EVIDENCE INCLUDING SECONDARY ENDPOINTS DID NOT SUPPORT A SIGNIFICANT TREATMENT EFFECT.PFIZER INC - PFIZER WILL CONTINUE TO REVIEW DATA.PFIZER INC - TERMINATING TWO ONGOING CLINICAL STUDIES EVALUATING DOMAGROZUMAB (PF-06252616).  Full Article

Exact Sciences CEO Expects Revenue Of About $700 Million In 2019
Wednesday, 22 Aug 2018 10:04am EDT 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES CEO SAYS PFIZER DEAL TO HAVE VERY LITTLE IMPACT ON COLOGUARD SALES IN 2018 - CONF CALL.EXACT SCIENCES EXPECTS REVENUE OF ABOUT $700 MILLION IN 2019 - CONF CALL.EXACT SCIENCES EXPECTS PFIZER DEAL TO HAVE IMPACT ON COLOGUARD SALES THROUGHOUT 2019 - CONF CALL.  Full Article

Therachon Raises $60 Million Mezzanine Financing
Thursday, 9 Aug 2018 07:03am EDT 

Aug 9 (Reuters) - Therachon AG::THERACHON RAISES $60 MILLION MEZZANINE FINANCING TO ADVANCE LEAD PROGRAM IN ACHONDROPLASIA AND TO EXPAND RARE DISEASE PIPELINE.THERACHON AG SAYS FINANCING LED BY NOVO HOLDINGS, JOINED BY COWEN HEALTHCARE INVESTMENTS, PFIZER VENTURES, AMONG OTHERS.  Full Article

Pfizer hit with multi-plaintiff suit over anti-seizure drug Dilantin

Pfizer Inc has been sued by 10 people alleging the company and its subsidiaries failed to warn of the risk of severe brain damage from its anti-seizure medication Dilantin.